Literature DB >> 8543307

Alterations of the retinoblastoma gene in clinically localized, stage B prostate adenocarcinomas.

M M Ittmann1, R Wieczorek.   

Abstract

Alterations of the retinoblastoma (Rb) tumor suppressor gene and its encoded protein have been detected in a variety of malignant neoplasms. The authors have evaluated a series of 26 clinically localized stage B prostate adenocarcinomas for loss of heterozygosity (LOH) at 13q14 (including the Rb locus), rearrangements or partial deletions of the Rb gene, and alterations of Rb protein level by quantitative immunohistochemistry. LOH at the Rb locus occurred in 35% of the informative specimens. Of the specimens that showed LOH, 33% also had decreased or absent Rb protein in tumor cells by quantitative immunohistochemistry. In contrast, none of the specimens without LOH showed loss of Rb protein. Thus, LOH is correlated with loss of Rb protein. The authors conclude that alterations of the Rb tumor suppressor gene occur in a significant fraction of stage B prostate adenocarcinomas.

Entities:  

Mesh:

Year:  1996        PMID: 8543307     DOI: 10.1016/s0046-8177(96)90134-3

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  13 in total

Review 1.  Time to stratify? The retinoblastoma protein in castrate-resistant prostate cancer.

Authors:  Ana Aparicio; Robert B Den; Karen E Knudsen
Journal:  Nat Rev Urol       Date:  2011-08-02       Impact factor: 14.432

2.  Assessment of the anticancer mechanism of ferulic acid via cell cycle and apoptotic pathways in human prostate cancer cell lines.

Authors:  Canan Eroğlu; Mücahit Seçme; Gülseren Bağcı; Yavuz Dodurga
Journal:  Tumour Biol       Date:  2015-06-30

3.  Common mutations in BRCA1 and BRCA2 do not contribute to early prostate cancer in Jewish men.

Authors:  K L Nastiuk; M Mansukhani; M B Terry; P Kularatne; M A Rubin; J Melamed; M D Gammon; M Ittmann; J J Krolewski
Journal:  Prostate       Date:  1999-08-01       Impact factor: 4.104

4.  The future in advanced prostate cancer: take your partners or is the last dance for me?

Authors:  David I Quinn
Journal:  Rev Urol       Date:  2004

Review 5.  From genomics to functions: preclinical mouse models for understanding oncogenic pathways in prostate cancer.

Authors:  Chuan Yu; Kevin Hu; Daniel Nguyen; Zhu A Wang
Journal:  Am J Cancer Res       Date:  2019-10-01       Impact factor: 6.166

Review 6.  The AR dependent cell cycle: mechanisms and cancer relevance.

Authors:  Matthew J Schiewer; Michael A Augello; Karen E Knudsen
Journal:  Mol Cell Endocrinol       Date:  2011-07-12       Impact factor: 4.102

Review 7.  Molecular biology of prostate cancer.

Authors:  X B Shi; P H Gumerlock; R W deVere White
Journal:  World J Urol       Date:  1996       Impact factor: 4.226

8.  1α,25-dihydroxyvitamin D3 inhibits C4-2 prostate cancer cell growth via a retinoblastoma protein (Rb)-independent G1 arrest.

Authors:  Michele N Washington; Jung-Sun Kim; Nancy L Weigel
Journal:  Prostate       Date:  2011-01-01       Impact factor: 4.104

Review 9.  Tailoring to RB: tumour suppressor status and therapeutic response.

Authors:  Erik S Knudsen; Karen E Knudsen
Journal:  Nat Rev Cancer       Date:  2008-09       Impact factor: 60.716

10.  RB/E2F1 as a Master Regulator of Cancer Cell Metabolism in Advanced Disease.

Authors:  Amy C Mandigo; Wei Yuan; Kexin Xu; Peter Gallagher; Angel Pang; Yi Fang Guan; Ayesha A Shafi; Chellappagounder Thangavel; Beshara Sheehan; Denisa Bogdan; Alec Paschalis; Jennifer J McCann; Talya S Laufer; Nicolas Gordon; Irina A Vasilevskaya; Emanuela Dylgjeri; Saswati N Chand; Matthew J Schiewer; Josep Domingo-Domenech; Robert B Den; Jeff Holst; Peter A McCue; Johann S de Bono; Christopher McNair; Karen E Knudsen
Journal:  Cancer Discov       Date:  2021-04-20       Impact factor: 39.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.